此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Safety and Tolerability of PRO-143 Ophthalmic Solution in Healthy Volunteers. (PRO-143)

2018年10月8日 更新者:Laboratorios Sophia S.A de C.V.

Study to Evaluate the Safety and Tolerability of Pro-143 Ophthalmic Solution in Healthy Volunteers.

Study to evaluate the safety and tolerability of PRO-143 solution ophthalmic in healthy volunteers.

研究概览

详细说明

A phase I, open label and unicentric clinical trial to evaluate the safety and tolerability of PRO-143 ophthalmic solution in healthy volunteers.

研究类型

介入性

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Jalisco
      • Guadalajara、Jalisco、墨西哥、44100
        • Independent Clinical Research Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Healthy male and female.
  • Age ≥ 18 years old at screening visit.

Exclusion Criteria:

  • Any ocular or systemic condition.
  • Patient with one blind eye.
  • Visual acuity of 20/40 in any eye.
  • Use of ocular or systemics medications.
  • Contraindications or sensitivity to any component of the study treatments.
  • Contact lens users.
  • Ocular surgery within the past 3 months..
  • Women who were not using an effective means of contraception or who were pregnant or nursing.
  • Participation in any studies of investigational drugs within 90 days previous to the inclusion.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:PRO-143 Ophthalmic Solution
PRO-143 Ophthalmic Solution applied four times per day (c/6 hours) during 10 days.
PRO-143 Ophthalmic Solution applied four times per day (C/6 hours) during 10 days.
其他名称:
  • PRO-143

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Conjunctival bulbar hyperemia
大体时间:10 days

Conjunctival hyperemia is defined as the simplest reaction of the conjunctiva to a stimulus, a red appearance secondary to the vasodilation of the conjunctival vessels of variable intensity. He will graduate using the Efron scale.

0 Normal , 1 Very slight, 2 Mild, 3 Moderate, 4 Severe.

10 days
Number of Participants with adverse events
大体时间:10 days
he evaluation of adverse events requires a questioning conducted by the principal investigator and the appropriate exploratory techniques for its detection. the number of adverse events per study group will be considered for the analysis
10 days

次要结果测量

结果测量
措施说明
大体时间
Intraocular pressure (IOP)
大体时间:10 days
Tonometry is the objective measure of Intraocular pressure, based primarily on the force required to flatten the cornea, or the degree of corneal indentation produced by a fixed force. Goldman's tonometry is based on the Imbert-Fick principle. the result will be expressed in millimeters of mercury and the comparison between groups will be carried out.
10 days
Visual ability (VA)
大体时间:10 days
The VA will be evaluated basally, without refractive correction with the Snellen chart. Which will be located in a place with adequate lighting, natural or artificial and at a distance of 3 meters from the subject to be evaluated
10 days
Eye comfort index (ICO)
大体时间:10 days

It is a questionnaire designed to measure the irritation of the ocular surface with Rasch analysis to produce estimates on a linear scale of intervals (ratings: 0-100). Similar to the index for ocular surface diseases, the ocular comfort index (ICO) evaluates symptoms. The ICO contains 6 items that focus on the discomfort associated with the ocular surface. Each of these questions has two parts, which inquire separately the frequency and severity of the symptoms.

The evaluator will deliver the questionnaire to the subject and allow the subject to answer it calmly without any pressure and / or coercion, will only assist him if he has difficulty understanding any of the questions.

10 days

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Leopoldo M Baiza-Durán, MD、Clinical Research Department. Laboratorios Sophia SA de CV
  • 首席研究员:José F Alaniz-De La O, MD、Independent Clinical Research Center
  • 首席研究员:Laura R Saucedo-Rodíguez, MD、Independent Clinical Research Center

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2013年11月1日

初级完成 (预期的)

2014年2月1日

研究完成 (预期的)

2014年3月1日

研究注册日期

首次提交

2012年2月22日

首先提交符合 QC 标准的

2018年10月3日

首次发布 (实际的)

2018年10月5日

研究记录更新

最后更新发布 (实际的)

2018年10月10日

上次提交的符合 QC 标准的更新

2018年10月8日

最后验证

2018年10月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅